ATE505203T1 - Pharmazeutische kombination aus aliskiren und valsartan - Google Patents

Pharmazeutische kombination aus aliskiren und valsartan

Info

Publication number
ATE505203T1
ATE505203T1 AT08835893T AT08835893T ATE505203T1 AT E505203 T1 ATE505203 T1 AT E505203T1 AT 08835893 T AT08835893 T AT 08835893T AT 08835893 T AT08835893 T AT 08835893T AT E505203 T1 ATE505203 T1 AT E505203T1
Authority
AT
Austria
Prior art keywords
aliskiren
valsartan
minutes
dose combination
fixed dose
Prior art date
Application number
AT08835893T
Other languages
English (en)
Inventor
Catherine Curdy
Shoufeng Li
Dieter Becker
Burkhard Schluetermann
Frederic Gerber
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of ATE505203T1 publication Critical patent/ATE505203T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT08835893T 2007-09-28 2008-09-24 Pharmazeutische kombination aus aliskiren und valsartan ATE505203T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US97590507P 2007-09-28 2007-09-28
PCT/US2008/077417 WO2009045796A1 (en) 2007-09-28 2008-09-24 Pharmaceutical combination of aliskiren and valsartan

Publications (1)

Publication Number Publication Date
ATE505203T1 true ATE505203T1 (de) 2011-04-15

Family

ID=40394241

Family Applications (1)

Application Number Title Priority Date Filing Date
AT08835893T ATE505203T1 (de) 2007-09-28 2008-09-24 Pharmazeutische kombination aus aliskiren und valsartan

Country Status (16)

Country Link
US (1) US20100247645A1 (de)
EP (1) EP2205279B1 (de)
JP (1) JP2010540548A (de)
KR (1) KR20100059912A (de)
CN (1) CN101808665A (de)
AT (1) ATE505203T1 (de)
AU (1) AU2008309059A1 (de)
BR (1) BRPI0817275A2 (de)
CA (1) CA2697437A1 (de)
DE (1) DE602008006243D1 (de)
ES (1) ES2364538T3 (de)
MX (1) MX2010003439A (de)
PL (1) PL2205279T3 (de)
PT (1) PT2205279E (de)
RU (1) RU2010116526A (de)
WO (1) WO2009045796A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI468191B (zh) * 2009-01-28 2015-01-11 Novartis Ag 有機化合物之調配物
AU2010226620A1 (en) * 2009-03-20 2011-09-22 Novartis Ag Galenical formulations of a fixed dose combination of Valsartan and Aliskiren
AR080683A1 (es) * 2010-03-16 2012-05-02 Novartis Ag Composiciones farmaceuticas de aliskiren y metodos de administracion
GB2479213B (en) * 2010-04-01 2013-07-10 Theravida Inc Pharmaceutical formulations for the treatment of overactive bladder
CA2835277A1 (en) 2011-05-10 2012-11-15 Theravida, Inc. Combinations of solifenacin and salivary stimulants for the treatment of overactive bladder
CN102247344A (zh) * 2011-05-30 2011-11-23 北京阜康仁生物制药科技有限公司 一种新型降血压组合物
CN102626395B (zh) * 2012-04-19 2014-02-26 海南美兰史克制药有限公司 一种阿利克仑缬沙坦药物组合物脂质体固体制剂
WO2013166114A1 (en) * 2012-05-01 2013-11-07 Althera Life Sciences, Llc Oral tablet formulation consisting of fixed combination of atorvastatin and ezetimibe
US10376470B2 (en) * 2012-05-01 2019-08-13 Althera Life Sciences, Llc Oral tablet formulation consisting of fixed combination of rosuvastatin and ezetimibe for treatment of hyperlipidemia and cardiovascular diseases
EP2844233B1 (de) * 2012-05-01 2020-05-06 Althera Life Sciences, LLC Orale tablettenformulierung aus einer fixierten kombination aus rosuvastatin und ezetimib zur behandlung von hyperlipidämie und herz-kreislauf-erkrankungen
WO2017127073A1 (en) 2016-01-20 2017-07-27 Theravida, Inc. Methods and compositions for treating hyperhidrosis

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7374779B2 (en) * 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
PE20142101A1 (es) * 2004-03-17 2014-12-27 Novartis Ag Composiciones farmaceuticas de aliskiren
PT1799199E (pt) * 2004-10-08 2012-07-03 Novartis Ag Uso de inibidores da renina para a prevenção ou tratamento da disfunção diastólica ou insuficiência cardíaca diastólica
US20100240760A1 (en) * 2005-03-22 2010-09-23 Jessie Gu Biomarkers for Efficacy of Aliskiren as a Hypertensive Agent
TWI405580B (zh) * 2005-06-27 2013-08-21 Sankyo Co 含有血管收縮素ｉｉ接受器拮抗劑及鈣通道阻斷劑之醫藥調配物

Also Published As

Publication number Publication date
DE602008006243D1 (de) 2011-05-26
WO2009045796A1 (en) 2009-04-09
MX2010003439A (es) 2010-04-21
US20100247645A1 (en) 2010-09-30
EP2205279B1 (de) 2011-04-13
PL2205279T3 (pl) 2011-09-30
AU2008309059A1 (en) 2009-04-09
BRPI0817275A2 (pt) 2015-06-16
ES2364538T3 (es) 2011-09-06
EP2205279A1 (de) 2010-07-14
PT2205279E (pt) 2011-07-11
KR20100059912A (ko) 2010-06-04
JP2010540548A (ja) 2010-12-24
CN101808665A (zh) 2010-08-18
CA2697437A1 (en) 2009-04-09
RU2010116526A (ru) 2011-11-10

Similar Documents

Publication Publication Date Title
ATE505203T1 (de) Pharmazeutische kombination aus aliskiren und valsartan
TN2010000135A1 (en) Galenical formulations of organic compounds
ECSP077999A (es) Formulaciones de una sal de bupropion de liberación modificada
CY1111470T1 (el) Νεες φαρμακευτικες συνθεσεις που περιεχουν φλιβανσερινη πολυμορφη α
ATE540680T1 (de) Pharmazeutische aripiprazol-zusammensetzungen
JP2007527914A5 (de)
IL183357A0 (en) Oral medicament for the modified release of at least one active principle, in multimicrocapsule form
CO6440564A2 (es) Composiciones farmacéuticas de liberación inmediata que comprenden oxicodona y naloxona
WO2007093183A3 (en) Use of a compound that enhances gabaa-ergic neurotransmission for the treatment of inflammatory diseases
UA93709C2 (ru) 12-имидазолил-1-додеканол и его применение b изготовлении фармацевтических композиций
RS52867B (en) GLATIRAMER ACETATOM AND RAZAGILIN COMBINED THERAPY FOR MULTIPLE SCLEROSIS
MX2009004017A (es) Usos de los compuestos carboxi-amido triazol y sus sales.
NZ628513A (en) Pharmaceutical for oral delivery comprising mgbg and methods of treating disease
BRPI1009392A2 (pt) "formulação farmacêutica, e, uso de uma quantidade farmaceuticamente eficaz de uma formulação farmacêutica."
AR054595A1 (es) Formulaciones/composiciones farmaceuticas de guanfacina apropiadas para forma de administracion diaria en una unica dosis
WO2008003050A3 (en) Gallium nitrate formulations
IL187632A (en) 17 – Ethinyl – 17 – Hydroxy – 13 – Methyl – 17,16,15,14,13,12,11,9,8,7 – Dachahydro – 6 h– Cyclopentane [a] Penanthran – 3 – Ilmethyl ester of acetoxy acid Acetic, a pharmaceutical dosage unit containing it and its use in the preparation of a contraceptive
JO3239B1 (ar) تركيبات جالينية من مركبات عضوية
AR067351A1 (es) Combinacion de picotamida con nafronil
WO2007071721A3 (en) Ginger extract for inhibiting human drug transporters
MXPA05007253A (es) Sales novedosas de derivados anticonvulsivantes.
TN2011000100A1 (en) Galenical formulations of organic compounds
ZA201005394B (en) 15,16-methylene-17-hydroxy-19-nor-21-carboxylic acid y-lactone derivative,use thereof,and medicament containing said derivative
MX2011009846A (es) Formulaciones galenicas de una combinacion de dosis fija de valsartan y alisquireno.
TW200833375A (en) Pharmaceutical compositions

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 2205279

Country of ref document: EP